SCHEMBL8709772

SCHEMBL8709772

O=C1CCN2CC=CC=C12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7215990 0.88 APAF1 (0.32)
SCHEMBL19004321 0.69
SCHEMBL27952709 0.60
SCHEMBL10515564 0.60 MAPT (0.31)
SCHEMBL1978035 0.59
SCHEMBL11228217 0.58
Hydrochloric Acid SCHEMBL3904361 0.58
SCHEMBL8576907 0.58
SCHEMBL28158852 0.57
SCHEMBL15063081 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors MIRATI THERAPEUTICS INC (US) 2024-06-27 US claimed
EP-4304720-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2024-01-17 EP claimed
WO-2022192745-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2022-09-15 WO claimed
EP-2922543-B1 SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2017-05-24 EP claimed
US-9273033-B2 Substituted pyridone derivatives as PDE10 inhibitors MERCK SHARP & DOHME CORP. (US) 2016-03-01 US claimed
US-20150291561-A1 SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-10-15 US claimed
EP-2922543-A1 SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-09-30 EP claimed
WO-2014081617-A1 SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-05-30 WO claimed
JP-10045762-A None JP disclosed
WO-2025217007-A1 COMBINATION THERAPIES USING PRMT5 INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER Mirati Therapeutics, Inc. (US) 2025-10-16 WO disclosed
WO-2025217008-A1 COMBINATION THERAPIES USING PRMT5 INHIBITORS AND SOS1 INHIBITORS FOR THE TREATMENT OF CANCER Mirati Therapeutics, Inc. (US) 2025-10-16 WO disclosed
WO-2025217015-A1 COMBINATION THERAPIES USING PRMT5 INHIBITORS AND KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER Mirati Therapeutics, Inc. (US) 2025-10-16 WO disclosed
US-20250312351-A1 COMBINATION THERAPIES USING PRMT5 INHIBITORS AND SOS1 INHIBITORS FOR THE TREATMENT OF CANCER Mirati Therapeutics, Inc. (US) 2025-10-09 US disclosed
US-20250312344-A1 COMBINATION THERAPIES USING PRMT5 INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER Mirati Therapeutics, Inc. (US) 2025-10-09 US disclosed
EP-2922543-B1 SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2017-05-24 EP disclosed
US-9273033-B2 Substituted pyridone derivatives as PDE10 inhibitors MERCK SHARP & DOHME CORP. (US) 2016-03-01 US disclosed
US-20150291561-A1 SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-10-15 US disclosed
EP-2922543-A1 SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-09-30 EP disclosed
WO-2014081617-A1 SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-05-30 WO disclosed
JP-H1045762-A PRODUCTION OF OXOTETRAHYDROINDOLIZINE DERIVATIVE DAI ICHI SEIYAKU CO LTD 1998-02-17 JP disclosed